Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693674 · ClinicalTrials.gov registry record · Phase 3
Effect of Sacubitril-Valsartan on Cardiac Structure and Function
A Phase 3 study of Congenital Heart Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06693674: Recruiting Phase 3 study of Congenital Heart Disease, sponsored by Mayo Clinic.
NCT06693674 is a Phase 3 study of Congenital Heart Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693674, a Phase 3 study of Congenital Heart Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Primary Outcome
Ventricular Function will be determined by indices of Right Ventricle (RV) and Left Ventricle (LV) systolic and diastolic function indices acquired from CMRI and transthoracic echocardiographic imaging.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Entresto Pill
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What NCT06693674 shows while recruiting
NCT06693674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06693674 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06693674 about?
NCT06693674 is a clinical study titled "Effect of Sacubitril-Valsartan on Cardiac Structure and Function". The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
What is the current status of trial NCT06693674?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2025-02-03. Estimated completion is 2026-12.
What conditions does trial NCT06693674 study?
This clinical trial studies the following conditions: Congenital Heart Disease.
What interventions are being tested in trial NCT06693674?
The interventions under investigation include: Placebo (OTHER), Entresto Pill (DRUG).
Who is sponsoring clinical trial NCT06693674?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693674 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06693674's enrollment target sits among peer trials
45 47th of 63 higher than 16 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
ACTIVE NOT RECRUITING · Phase 3
-
Acute Normovolemic Hemodilution in Complex Cardiac Surgery
COMPLETED · Phase 3
-
Fontan Fitness Trial
RECRUITING · NA
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
RECRUITING
-
A Study of Invasive Hemodynamic for MACHD Registry
RECRUITING
-
Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI